Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S, Schoemmel M, Kraemer M, Bruns C, Schroeder W, Zander T, Gebauer F, Alakus H, Merkelbach-Bruse S, Buettner R, Loeser H, Thelen M, Schlößer HA, Quaas A. Wagener-Ryczek S, et al. Cancer Immunol Immunother. 2020 Apr;69(4):523-533. doi: 10.1007/s00262-019-02475-w. Epub 2020 Jan 20. Cancer Immunol Immunother. 2020. PMID: 31960110 Free PMC article.
Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation.
Heydt C, Wölwer CB, Velazquez Camacho O, Wagener-Ryczek S, Pappesch R, Siemanowski J, Rehker J, Haller F, Agaimy A, Worm K, Herold T, Pfarr N, Weichert W, Kirchner T, Jung A, Kumbrink J, Goering W, Esposito I, Buettner R, Hillmer AM, Merkelbach-Bruse S. Heydt C, et al. BMC Med Genomics. 2021 Feb 27;14(1):62. doi: 10.1186/s12920-021-00909-y. BMC Med Genomics. 2021. PMID: 33639937 Free PMC article.
Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue.
Vollbrecht C, Hoffmann I, Lehmann A, Merkelbach-Bruse S, Fassunke J, Wagener-Ryczek S, Ball M, Dimitrova L, Hartmann A, Stöhr R, Erber R, Weichert W, Pfarr N, Bohlmann L, Jung A, Dietmaier W, Dietel M, Horst D, Hummel M. Vollbrecht C, et al. Among authors: wagener ryczek s. Virchows Arch. 2023 Apr;482(4):697-706. doi: 10.1007/s00428-022-03445-x. Epub 2022 Nov 11. Virchows Arch. 2023. PMID: 36367572 Free PMC article.
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
Riedel R, Fassunke J, Tumbrink HL, Scheel AH, Heydt C, Hieggelke L, Scheffler M, Heimsoeth A, Nogova L, Michels S, Weber JP, Fischer RN, Eisert A, Westphal T, Schaufler D, Siemanowski J, Ihle MA, Wagener-Ryczek S, Castiglione R, Pappesch R, Rehker J, Jürgens J, Stoelben E, Bunck A, Kobe C, Merkelbach-Bruse S, Sos ML, Büttner R, Wolf J. Riedel R, et al. Among authors: wagener ryczek s. Eur J Cancer. 2023 Jan;179:124-135. doi: 10.1016/j.ejca.2022.11.010. Epub 2022 Nov 15. Eur J Cancer. 2023. PMID: 36521334
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.
Riedel R, Fassunke J, Scheel AH, Scheffler M, Heydt C, Nogova L, Michels S, Fischer RN, Eisert A, Scharpenseel H, John F, Ruge L, Schaufler D, Siemanowski J, Ihle MA, Wagener-Ryczek S, Pappesch R, Rehker J, Bunck A, Kobe C, Keil F, Merkelbach-Bruse S, Büttner R, Wolf J. Riedel R, et al. Among authors: wagener ryczek s. J Thorac Oncol. 2024 Jan;19(1):160-165. doi: 10.1016/j.jtho.2023.06.020. Epub 2023 Jul 8. J Thorac Oncol. 2024. PMID: 37429463
22 results